Modulateur Prébiotique du Microbiome pour Réduire les Effets Secondaires Gastro-Intestinaux de la Metformine chez les Jeunes Atteints de Diabète de Type 2

Date de début de l'étude : 10 mars 2020

* INCLUSION CRITERIA: 1. Age 10-25 years 2. Pubertal or post-pubertal: Girls - Tanner stage IV-V breast; Boys - Testicular volume \>10cc 3. Diagnosis of type 2 diabetes by American Diabetes Association (ADA) guidelines \[36\] or with established diagnosis previously treated with metformin. 4. Negative test for diabetes-related autoantibodies (glutamic acid decarboxylase 65 and tyrosine phosphatase-related islet antigen 2 (IA-2)) documented in NIH CRIS chart or via outside laboratory assessment within the last 10 years. 5. Hemoglobin A1C \<8% at study initiation EXCLUSION CRITERIA: 1. Pregnancy or breastfeeding 2. Allergy to study medications 3. Allergy or self-reported intolerance to blueberry, pomegranate, or oats, soy, gluten or dairy products. 4. Chronic insulin therapy or insulin use within the last 3 months 5. Treatment with other medications which are known to affect the parameters under study, including antibiotics within the last month, immunosuppressants, proton-pump inhibitors, supraphysiologic systemic steroids, probiotic or prebiotic supplements 6. Heavy yogurt consumption (2 or more servings of \>=6 oz per day) 7. Chronic GI disease, gastric bypass surgery, cancer diagnosis or autoimmune disease 8. Metabolic derangement such as metabolic acidosis, severe hyperglycemia (fasting blood glucose \>= 200mg/dL), and/or liver enzymes \> three times the upper limit of normal. 9. Any other condition that, in the opinion of the investigators, will increase risk to the subject, or impede the accurate collection of study-related data. 10. Body weight \>= 450lbs 11. Body weight \<=58kg 12. Hemoglobin concentration \<10g/dL